Results 281 to 290 of about 484,364 (380)

Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I.
Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S. Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera‐McDonough, Murat Yildirim, Ric M. Procyshyn, Craig Chepke, Julie Passarell   +10 more
wiley   +1 more source

Fool's-gold science : The ethical and scientific perils of testing most vaccines using placebo-controlled randomized trials. [PDF]

EMBO Rep
Caplan A, Pasadyn FL, Mamo N.
europepmc   +1 more source

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger, Carina Holmqvist, Daniël M. Jonker, Bjarke M. Klein, Lorien E. Urban   +4 more
wiley   +1 more source

Investigating the effects of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine: a protocol for a randomized, triple-blind, placebo-controlled trial. [PDF]

Trials
Golpour-Hamedani S, Bagherniy M, Khorvash F, Feizi A, Sharma M, Askari G.   +5 more
europepmc   +1 more source

Formoterol, a new long-acting selective β-adrenergic receptor agonist: Double-blind comparison with salbutamol and placebo in children with asthma

, 1989
A BECKER, F. Estelle R. Simons
openalex   +1 more source

Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses

Cancer Communications, EarlyView.
Seungbyn Baek, Junha Cha, Min Hee Hong, Gamin Kim, Yoon Woo Koh, Dahee Kim, Wonrak Son, Chan‐Young Ock, Seungeun Lee, Martin Hemberg, Seong Yong Park, Hye Ryun Kim, Insuk Lee   +12 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma. [PDF]

Ther Adv Med Oncol
Meyers BM, Lim HJ, Brahmania M, Liu DM, Tam VC, McLeod D, Ramjeesingh R, Knox JJ, Vogel A.   +8 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study

, 1987
Adam Timmis, Brian P. Griffin, J. C. P. Crick, E Sowton   +3 more
openalex   +1 more source